KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

LifeMD (LFMD) Research & Development (2019 - 2025)

LifeMD filings provide 7 years of Research & Development readings, the most recent being -$920045.0 for Q4 2025.

  • On a quarterly basis, Research & Development fell 276.07% to -$920045.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $7.3 million, a 7.13% increase, with the full-year FY2025 number at $7.3 million, up 7.13% from a year prior.
  • Research & Development hit -$920045.0 in Q4 2025 for LifeMD, down from $2.8 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $2.8 million in Q3 2025 to a low of -$920045.0 in Q4 2025.
  • Median Research & Development over the past 5 years was $1.1 million (2022), compared with a mean of $1.2 million.
  • Biggest five-year swings in Research & Development: skyrocketed 541.23% in 2022 and later crashed 276.07% in 2025.
  • LifeMD's Research & Development stood at $216979.0 in 2021, then skyrocketed by 369.71% to $1.0 million in 2022, then surged by 96.04% to $2.0 million in 2023, then tumbled by 112.24% to -$244650.0 in 2024, then crashed by 276.07% to -$920045.0 in 2025.
  • The last three reported values for Research & Development were -$920045.0 (Q4 2025), $2.8 million (Q3 2025), and $2.7 million (Q2 2025) per Business Quant data.